A metabolically active human dermal replacement for the treatment of diabetic foot ulcers

Artificial Organs

Volumn 21, Issue 11, 1997, Pages 1203-1210

  Naughton, Gail ^a   Mansbridge, Jonathan ^a   Gentzkow, Gary ^a  

^a Advanced Tissue Sciences Liquidating Trust   (United States)

Author keywords

Diabetic foot ulcers; Human dermal replacement; Metabolic activity; Tissue engineering

Indexed keywords

DISEASES; HISTOLOGY; METABOLISM; TISSUE;

DERMAL REPLACEMENT; DERMAL TISSUES; DIABETIC FOOT ULCER; DIABETICS PATIENTS; GROWTH FACTOR; HUMAN DERMAL REPLACEMENT; LIVING HUMAN TISSUE; METABOLIC ACTIVITY; NORMAL GROWTH; TISSUES ENGINEERINGS;

TISSUE ENGINEERING;

BIOMATERIAL; GROWTH FACTOR; MATRIX PROTEIN;

CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC FOOT; FOOT ULCER; HEALING; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; SKIN GRAFT; SKIN TRANSPLANTATION; TISSUE METABOLISM; TREATMENT OUTCOME; ULCER HEALING;

EID: 0030733932     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1594.1997.tb00476.x     Document Type: Conference Paper

References (21)

1. Cooper ML, Hansbrough JF, Spielvogel RL, Cohen R, Bartel R, Naughton G. In vivo optimization of a living dermal substitute employing cultured human fibroblasts on a biodegradable polyglycolic acid or polyglactin mesh. Biomaterials 1991; 12:243-8.
2. Landeen LK, Zeigler FC, Halberstadt C, et al. Characterization of a human dermal replacement. Wounds 1992;5:167-75.
3. Kruse PF Jr, Patterson MK Jr, eds. Tissue culture methods and applications. New York: Academic Press, 1973.
4. Jakoby WB, Pastan IH, eds. Cell culture. Methods in enzymology. 1979:58.
5. U.S. Food and Drug Administration. Points to consider in the characterization of cell lines used to produce biologicals. Bethesda, MD: U.S. Department of Health and Human Services, May 1993.
6. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy (1989). Notes to applicants for marketing authorizations on the production and quality control of monoclonal antibodies of murine origin intended for use in man. J Biol Stand 1989;17:213.
7. Blood S, Heck E, Baxter CR. The importance of the bacterial flora in cadaver homograft burn donor skin. Proceedings of the 11th Meeting of the American Burn Association, New Orleans, 1979:79-80.
8. White MJ, Whalen JD, Gould JA, et al. Procurement and transplantation of colonized cadaver skin. Am Surg 1991;57: 402-7.
9. Contard P, Bartel RL, Jacobs L, et al. Culturing keratinocytes and fibroblasts in a three-dimensional mesh results in epidermal differentiation and formation of a basal lamina-anchoring zone. J Invest Dermatol 1993;100:35-9.
10. Sternberg M, Cohen-Forterre L, Peyroux J. Connective tissue in diabetes mellitus: Biochemical alterations of the intercellular matrix with special reference to proteoglycans. Diabetes Metab 1985;11:27-50.
11. National Institutes of Health, National Institute of Diabetes and Digestive Diseases. Diabetes in America, 2nd ed. Washington, D.C.: Government Printing Office, 1995:409-29. (NIH Publication No. 95-1468.)
12. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation: Basis for prevention. Diabetes Care 1990;13: 513-21.
13. Brindley GW, Cofield RH. Local treatment for neuropathic foot ulceration and osteoarthropathy. Foot Ankle 1985;5(5): 245-50.
14. Edmonds ME, Blundell MP, Morris ME, Thomas EM, Cotton LT, Watkins PJ. Improved survival of the diabetic foot: The role of a specialized foot clinic. Q J Med 1986;232:763-71.
15. Kerstein MD, Polsky S. Treating wounds associated with decreased sensibility. Ostomy/Wound Management 1995;41(2): 46-51.
16. Levin ME. Pathogenesis and management of diabetic foot lesions. In: Levin ME, O'Neal LW, Bowker JH, eds. The diabetic foot, 5th ed. St. Louis, MO: Mosby Year Book, Inc., 1993, 17-57.
17. Myerson M, Papa J, Eaton K, Wilson K. The total-contact cast for management of neuropathic plantar ulceration of the foot. J Bone Joint Surg 1992;74-A(2):261-9.
18. Steed DL, Diabetic Ulcer Study Group. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 1995; 21:71-81.
19. Knighton DR, Ciresi K, Fiegel VD, Schumerth S, Butler E, Cerra F. Stimulation of repair in chronic, nonhealing, cutaneous ulcer using platelet-derived wound healing formula. Surg Gynecol Obstet 1990;170:56-60.
20. Gentzkow GD, Iwaski SD, Hershon KS, Mengel M, Pendergast JJ, Ricotta JJ, Steed DP, Lipkin S. Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996;4:350-4.
21. Mustoe TA, Siddiqui A. Transforming growth factor beta 3 (TGF-β) accelerates wound healing without alteration of scar prominence. Histologic and competitive reverse-transcription-polymerase chain reaction studies. Arch Surg 1997;132(7): 753-60.